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Background: The clinical utility of DNA methylation as a predictive or prognostic biomarker requires scalable
resequencing protocols for bisulfite-converted DNA. Key features of any validation method should be adaptability
for low- or high-throughput needs and high reproducibility, and should only require minimal amounts of precious
clinical sample as input material. Critically, this method should also deliver robust results when working with
bisulfite-converted DNA extracted from formalin-fixed, paraffin-embedded (FFPE) blocks.
Results: We report here for the first time on comparison studies between the Fluidigm Access Array system and
multiplex assays for multiplex bisulfite PCR resequencing. The requirement of the Fluidigm Access Array system for high
template amounts and its sensitivity to variations in template quality rendered it unsuitable for bisulfite PCR applications
utilizing FFPE DNA. In response to this limitation, we established a multiplex bisulfite PCR assay capable of delivering
robust methylation data using minimal amounts of FFPE clinical DNA. To evaluate the parameters and reproducibility of
this assay, 57 amplicons were used to prepare sequencing libraries in triplicate for 13 FFPE tumour samples, as well as a
series of 5 methylated controls (0%, 25%, 50%, 75%, and 100%). Analysis of this data demonstrated that this multiplex
assay had high reproducibility (mean standard deviation of 1.4% for methylation values), was low cost, required low
sample input (50 ng of DNA or less), and could be scaled for both low- and high-throughput needs. Notably, ExoSAP-IT
(exonuclease I) treatment to remove residual primers in bisulfite resequencing libraries appeared to degrade the library
and generate a high-molecular weight smear which may impact on the degree of methylation assessed.
Conclusions: Multiplex bisulfite PCR assays represent a convenient and scalable method for validation and screening of
methylated DNA regions from archival FFPE DNA. Moreover, the library construction process detailed here can be rapidly
optimized and implemented with a minimal amount of work, can be performed using the standard equipment
found in any molecular biology laboratory, and can be easily adapted for use on both genomic DNA and bisulfite
DNA applications. However, in preparing bisulfite libraries for sequencing, the use of ExoSAP-IT is not recommended
due to potential off-target nuclease effects which may impact downstream methylation analysis.
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The methylation of cytosine at the carbon 5 position
(5-methylcytosine) is an epigenetic mark associated
with gene regulation [1]. In particular, in mammals,
methylation of cytosine residues in the context of
cytosine-guanine (CpG) dinucleotides [2,3] is involved* Correspondence: d.korbie@uq.edu.au; m.trau@uq.edu.au
1Centre for Personalised Nanomedicine, The University of Queensland,
St Lucia 4072, QLD, Australia
2 Australian Institute for Bioengineering and Nanotechnology, The University
of Queensland, Corner College and Cooper Rds (Bldg 75), St Lucia 4072,
QLD, Australia
Full list of author information is available at the end of the article
© 2015 Korbie et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.in mechanisms of X chromosome inactivation and epi-
genetic imprinting (that is, the ‘molecular memory’ of
genes), as well as the regulation of gene expression in a
tissue-specific manner [1,4,5], and aberrant patterns of
DNA methylation are associated with developmental path-
ologies and disease [6]. The role of DNA methylation in
cancer has received particular focus over the past 5 years,
which is reflected in the decision of the major sequencing
initiatives to pursue genome-wide DNA methylation ana-
lysis as one of their research goals (for example, The Can-
cer Genome Atlas [TCGA], [7] and [8], and International
Cancer Genome Consortium, [9]).This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cellent potential as a predictive or prognostic biomarker in
the aetiology and progression of cancer. To this end, can-
cer biomarker discovery projects have utilized a spectrum
of techniques to generate DNA methylation data which
in turn has driven advances in DNA methylation ana-
lysis technology, and data from multiple genome-scale
methylome projects at single-base-pair resolution is
now available [10]. However, the clinical utility of any
methylated DNA biomarker requires independent qualita-
tive and quantitative validation, ideally in independent labs
using orthologous techniques to those used in the original
discovery project. Moreover, key features of any validation
method should be scalability (that is, the capacity to be
adapted for low-, moderate-, or high-throughput needs),
reproducibility, and the requirement for minimal amounts
of precious clinical sample as input material.
Here, we report on the assessment of bisulfite resequen-
cing assays for analysis of methylation in clinical formalin-
fixed, paraffin-embedded (FFPE) samples. This analysis
involved extensive characterization of the Fluidigm Access
Array (Fluidigm, South San Francisco, CA, USA) platform
and culminated with the development of a separate multi-
plex bisulfite PCR assay capable of delivering robust methy-
lation data when using FFPE clinical DNA. Key features of
the assay are its low cost, low sample input (critical for lim-
ited and precious clinical samples), high reproducibility,
and scalability for both low- and high-throughput needs.
Moreover, the library construction can be performed using
the standard equipment found in any molecular biology
laboratory, making it accessible for the majority of labs.
Results and discussion
Recent reports have detailed microfluidic multiplex PCR
(MMP-seq) as providing a robust solution for comprehen-
sive, reliable, and high-throughput genetic profiling
of clinical tumour samples [11]. MMP-seq utilizes the
Fluidigm Access Array system, which employs microflui-
dic technology to concurrently amplify 48 or 96 samples
against an equal number of primer sets. However, while
the Fluidigm Access Array platform has been used for
somatic mutation screening of clinical FFPE DNA samples,
to date, the use of the platform for methylation analysis
has only been reported once [12], and its overall efficacy in
bisulfite PCR applications utilizing degraded clinical FFPE
DNA has not been evaluated. To this end, we embarked
on a series of optimization and characterization experi-
ments to assay the overall performance of the Access Array
system in high-throughput methylation analysis.
Assessing fusion primer sequences on bisulfite PCR
fidelity
To enable easy preparation of individual amplicon libraries
for sequencing, Access Array protocols utilize a fusionprimer strategy wherein universal forward and reverse
adaptor sequences are added to the 5′ ends of all primers.
After the initial gene-specific amplification, sample-specific
barcodes and platform-specific sequencing primers (for
example, MiSeq or Ion PGM) can then be added using
a second round of ‘barcoding’ PCR. However, the inclu-
sion of a 5′ adaptor sequence in bisulfite PCR primers can
be problematic due to the relative sequence degeneracy of
a bisulfite-converted DNA genome, which leads to ex-
tended A or T homopolymer stretches in the sample,
resulting in a lack of sequence complexity in PCR primers.
The lack of sequence complexity promotes primer self-
annealing, leading to off-target effects and PCR ‘dimers’
which can result in a reduction of sequencing depth if the
dimers are not effectively removed. As such, although the
addition of 20- to 25-bp fusion sequences at the 5′ end of
PCR primers simplifies downstream library construction, it
also increases the risk of producing dimerization artefacts
leading to a decrease in library quality.
To assess the impact of 5′ fusion sequences in bisulfite
PCR applications, three different sets of fusion primers
were evaluated across seven different genes for their suit-
ability: M13 fusion sequences, fusion primers incorporating
Ion Torrent sequencing adaptor sequences, and Fluidigm’s
CS fusion sequences. The results from this screen demon-
strate that while all primers produced single products
under stringent amplification conditions, the M13 and Ion
fusion sequences produced pronounced primer dimer
products in negative controls (Additional file 1: Figure S1);
in comparison, the Fluidigm CS fusion sequences did not
generate dimer products in any of the screening reactions,
which suggests that in situations where the template was
limiting, the CS sequences may perform better. Based on
this result, the CS1 and CS2 sequences were selected for
further use, and all future experiments employed CS fusion
primers.
Multiplex pre-amplification of bisulfite-converted
cell line DNA
The Access Array system recommends using 50 ng of
DNA as the template input amount, in a total volume of 5
μl; assuming that 1 ng of DNA is equivalent to 333 copies,
this equals approximately 100 copies of DNA in one Flui-
digm nanowell (refer to ‘Methods’ for these calculations).
Given DNA degradation due to FFPE fixation and extrac-
tion, together with potential inaccuracies in DNA quanti-
tation, it was therefore considered likely that the number
of PCR-amplifiable copies of DNA present would be con-
siderably less than 100 if the recommended DNA input
amount was followed. Limited DNA in the initial bisulfite
reaction can result in substantial PCR bias [13] particularly
if heterogeneous DNA methylation is present in a sample
(for example, due to variable tumour load within a sample).
Although increasing the total amount of DNA template
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with a limiting amount of DNA copies, only 28% of in-
put material ever participates in amplification on an
Access Array chip nanowell (refer to ‘Methods’ for this
calculation); as such, increasing DNA input amount
would always sacrifice 72% of the total sample, which is
an untenable alternative when working with limited
clinical DNA. For these reasons, pre-amplification pro-
tocols were assessed for their performance on bisulfite-
converted DNA, as a way to leverage greater utility out
of limited sample input.
To assess pre-amplification as a strategy for working
with bisulfite-converted DNA, individual primer pairs
were first screened against control cell line DNA. Only
amplicons that produced clear distinct products with no
observable secondary bands were selected for use in pre-
amplification, and based on this, 48 primer pairs wereA
Figure 1 Pre-amplification multiplex results for bisulfite DNA samples
with respect to multiplexability, pooling, and exonuclease treatment. (B)
pre-amplification. Forty-eight primer pairs were assessed for the multiplexabili
input DNA. Lane 1: A positive control involving singleplex PCR reaction of an
the pre-amplification. Lane 2: Eight-plex pre-amplification reaction and ExoSA
singleplex amplification (as illustrated in the upper panel of A). Lane 3: Result
treatment of the combined pool, for a total of 24 amplicons in the ExoSA
(as illustrated in the lower panel of A). Lane 4: Twenty-four-plex pre-amp
libraries, as compared to gDNA amplicons. The arrow indicates where pri
barcoding PCR. Lane 2: Sample library after barcoding PCR. Primers are visible
at 37°C. Lane 4: Sample library after ExoSAP-IT treatment at 37°C, followed by h
weight smear in the methylation library, which is not observed with gDN
heat denaturation step, but with no ExoSAP-IT.identified. Non-overlapping primer pairs were then pooled
into three combinations: eight different 8-plex pools, two
24-plex pools, and one 48-plex pool, after which each
multiplex pool underwent 15 rounds of PCR. This pre-
amplification PCR was followed by ExoSap-IT treatment
to remove residual primers, in an attempt to increase the
fidelity of downstream singleplex PCR by removing inter-
fering oligos.
Based on the pre-amplification pools and ExoSAP-IT pa-
rameters outlined above, four different pre-amplification
screening conditions were assessed, as outlined in
Figure 1A:
1. Eight-plex pre-amplification pools wherein each
8-plex pool was treated with ExoSAP-IT individually
to remove residual primers after pre-amplification,
prior to second-round singleplex PCRB
C
. (A) A flow diagram outlining the different conditions examined
The results of different conditions after 15 cycles of multiplex
ty in a pre-amplification reaction. All samples had the same amount of
individual primer pair, with the same DNA template amount as used in
P-IT treatment of individual pre-amp reactions, followed by pooling and
s of three different 8-plex reactions pooled together first then ExoSAP-IT
P-IT treatment, followed by singleplex amplification of a primer pair
lification results. (C) The effect of ExoSAP-IT treatment on bisulfite
mers migrate on the gel. Lane 1: Pool of 48 amplicons prior to
at the bottom of the lane. Lane 3: Sample library after ExoSAP-IT treatment
eat inactivation of the ExoSAP-IT at 80°C. Note the higher molecular
A amplicons. Lane 5: Sample library cycled at 37°C, followed by 80°C
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reactions together (for a total of 24 amplicons),
followed by ExoSAP-treatment of the combined
24-pool, then individually amplifying
3. A combined 24-plex pre-amplification, followed by
second-round singleplex PCR
4. A combined 48-plex pre-amplification, followed by
second-round singleplex PCR
Singleplex reactions were run with each primer pair as a
positive control, and representative results are shown in
Figure 1B. Preliminary results with cell line DNA demon-
strated that the pre-amplification successfully increased
the number of available copies in second-round PCR
(Figure 1B, Amplicon 1, lanes 1 and 2), and up to 24
primer pairs could be pooled together and then amplified
individually with no observable dimer effects. However,
48-plex pre-amplification resulted in substantial dimer
product after second-round singleplex PCR (data not
shown), and for this reason, 24-plex amplification was
selected as the ideal condition.
The pre-amplification pool was then used to individually
amplify each of the 48 targeted regions on a standard ther-
mocycler, after which an aliquot of each amplicon was
pooled together to construct the sequencing library. Prior
to the final barcoding PCR (wherein sequencing adaptors
and sample specific barcodes are added), ExoSAP-IT was
again used to remove residual gene-specific primers. This
step was required because many amplicons were partially
overlapping, and if residual primers are not removed,
smaller subproducts could be generated leading to a se-
quencing library dominated by small amplicon species
(data not shown). However, while ExoSAP-IT successfully
removed residual primers, exonuclease treatment of bisul-
fite resequencing libraries appeared to generate a smear of
high-molecular weight products not present in the ori-
ginal sample, whereas a similar effect was not observed
using genomic DNA (gDNA) amplicons (Figure 1C).
This effect was reproducibly observed only with bisul-
fite libraries and only when the heat denaturation step
to inactivate the ExoI/SAP enzymes was included; when
the heat inactivation step was omitted, no high-molecular
weight smears are observed. Moreover, this is not at-
tributable to exposure to heat, as thermal cycling of the
sample library in the absence of ExoSAP-IT does not
produce high-molecular smearing of the methylation
library (Figure 1C). Although the smeared high-molecular
weight product could be used for sequencing (data not
shown), due to concerns that off-target nuclease effects
could potentially introduce bias towards or against
methylated sequences, the use of ExoSAP-IT was dis-
continued and Agencourt XP beads (Beckman Coulter,
Inc., Fullerton, CA, USA) were used to remove residual
primers instead.Multiplex pre-amplification of bisulfite-converted FFPE
clinical DNA
The above control experiments with high-quality cell line
DNA indicated good overall performance of the bisulfite
PCR pre-amplification assay in producing a final library,
and therefore the utility of the assay using clinical FFPE
DNA was then assessed. To this end, 13 FFPE breast
tumour samples, as well as a series of 5 methylated con-
trols (0%, 25%, 50%, 75%, and 100%), were evaluated in the
pre-amplification strategy outlined above, which involved
44 well-performing primer pairs divided between two
20-plex and 24-plex pre-amplification pools which under-
went 15 cycles of pre-amplification. An aliquot of this mix
was then used in 44 individual singleplex PCR reactions
(one for each primer pair) for another 35 cycles, using a
standard PCR thermocycler. After checking all products
by gel, an aliquot of each amplicon was pooled together
followed by 15 rounds of barcoding PCR amplification
and finally gel purification; these libraries were observed
to give prominent single bands with no visible dimer
product (Figure 2A) and were successfully sequenced.
Sequenced libraries demonstrated high mappability (that
is, over 90% of reads mapped to the reference index); how-
ever, it was noted that the methylated controls included in
the analysis were below the methylation percentages ex-
pected, suggesting potential bias towards unmethylated
transcripts (Figure 2B), possibly as a result the total
number of cycles used (15 pre-amp + 35 secondary + 15
barcoding = 60 cycles of amplification).
The above experiments demonstrated that the pre-
amplification process was working successfully, and there-
fore to assess the performance of the Access Array plat-
form, the same pre-amplification samples previously used
were directly loaded onto a 48 × 48 Access Array micro-
fluidic chip and subjected to the same amplification,
purification, and barcoding parameters. However, li-
braries prepared using the Access Array chip were all
noted to produce strong dimer products, with many
samples showing no library present at the expected size
(Figure 2C). Despite repeated attempts, no high-quality
libraries were generated from these samples using the
Access Array system, in contrast to the prior success in
manually amplifying up individual primer pairs (Figure 2A).
Given the weak performance of the Access Array
chip compared to low-throughput methods, extensive
optimization experiments were then conducted to de-
termine the potential factors that could impact overall
amplification fidelity and yield when working with bi-
sulfite resequencing libraries. As the presence of dimer
products in the preliminary optimization experiments
was typically only observed in negative control experi-
ments (Additional file 1: Figure S1), it was concluded that
poor performance of the Access Array system could be




Figure 2 Bisulfite libraries prepared using the Fluidigm Access Array system. (A) Low-throughput libraries prepared manually were observed
to produce strong dominant bands of the expected size with minimal visible dimer product, when visualized by agarose gel. Size in base pairs
is indicated to the left (B) Sequencing results for the percent global methylation of the control libraries prepared manually. (C) Preliminary
results with the Fluidigm Access Array platform resulted in weakly amplifying sequencing libraries with prominent dimer products. (D) After
extensive optimization to identify the critical parameters, pre-amplification under ideal conditions still gave variable library performance using
the Access Array system, with minor differences in pre-amplification primer concentration or the number of cycles of pre-amplification leading
to failed libraries (that is, lane 1 vs lane 2). Lane 1, 200 nM primer, 15 cycles pre-amplification, GoTaq Flexi buffer; lane 2, 50 nM primer, 15 cycles
pre-amplification, GoTaq Flexi buffer; lane 3, 200 nM primer, 15 cycles pre-amplification, Roche HF buffer; lane 4, 200 nM primer, 20 cycles
pre-amplification, GoTaq Flexi buffer; lane 5, 50 nM primer, 20 cycles pre-amplification, GoTaq Flexi buffer; lane 6, 200 nM primer, 20 cycles
pre-amplification, Roche HF buffer.
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template quality due to FFPE degradation and bisul-
fite conversion. As such, it was hypothesized that in-
creasing the number of copies generated during the
pre-amplification step could potentially improve Access
Array performance.
To identify the critical pre-amplification parameters
necessary when using the Access Array for bisulfite
PCR, an extensive series of optimization experiments
was conducted: 24 different pre-amp conditions were
evaluated which investigated the effect of varying the
number of PCR cycles (15 to 30 cycles), annealing
temperature (55°C to 72°C), primer concentration (25 to
200 nM), MgCl2 concentration (1.5 to 7.5 mM), differentfinal concentrations of Taq buffer (0.25× to 2×), different
PCR buffers (GoTaq Flexi [Promega, Madison, WI, USA],
Roche High Fidelity [Roche Life Science, Indianapolis, IN,
USA]), cycling conditions (touch-up, touch-down, and
standard PCR amplification), and enhancer formula-
tions and concentrations (DMSO, betaine, BSA, DTT,
formamide). Despite extensive optimizations to identify
the critical parameters in pre-amplification, performance
with the Access Array platform was still variable and it
was observed that subtle differences in the number of
cycles and total final pre-amplification primer concentra-
tion could dramatically affect final library results (that is,
50 vs 200 nM primer pool or 15 vs 20 cycles of pre-
amplification PCR; Figure 2D).
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Initial experiments with 24-plex pre-amplification bisulfite
pools had demonstrated that pre-amplification of bisulfite
libraries could be used to increase the number of available
copies of the template (Figure 1B, lanes 1 and 4). Based on
this observation, it was hypothesized that if conditions
were sufficiently optimized, it should be possible to take
the pre-amplification pool template and directly perform
the barcoding PCR step, without an intermediate second-
stage amplification on the Access Array chip.
Initial optimization experiments were conducted with
gDNA amplicons. gDNA primers were run in real-time
quantitative PCR (qPCR) under standard conditions, and
two different final concentrations of primers were assessed
(300 vs 100 nM). Under these conditions, Cts were ob-
served to range from 18.2 to 38.5, and based on the re-
sults, primer pairs with proximal Ct values were pooled
together, taking care to ensure that primers for overlap-
ping regions were separated. This gave seven pools con-
taining five primer pairs each, after which each pool was
then amplified at final concentrations of 1,500, 500, 300,
and 100 nM to assess the effect to of primer concentration
on amplicon proportionality in the final library. After
amplification, each pool concentration was combined and
sequenced on both MiSeq and Ion Torrent platforms to
compare reproducibility of representation. Amplicon rep-
resentation across the four samples was normalized per
pool and the proportion of each amplicon in the final sam-
ple assessed (Additional file 2: Figure S2b); the highest
primer concentrations were observed to give the most
normalized coverage, with increasing variation in ampli-
con counts as final primer concentration became more
dilute, an effect which was independent of sequencing
platform. However, while higher primer concentrations led
to a more normalized coverage, they were also observed to
generate more dimer products (data not shown).
To determine which bisulfite PCR primer pairs should
be pooled together, a similar strategy was employed. In
brief, real-time qPCR was performed for 84 different
amplicons; Cts ranged from 25.5 to 37.1. Based on these
results, primer pairs with proximal Ct values were pooled
together, taking care to ensure that primers for overlap-
ping regions were separated, which resulted in 59 ampli-
cons spread across 8 pools (five pools of 8, two pools of 6,
and one pool of 5). Initial screening of the pools evaluated
different final primer pool concentrations (from 1 μM
final to 125 nM final) as well as different cycling parame-
ters, enhancers, and MgCl2 concentrations; two primer
pairs were excluded due to their tendency to cause dimers.
After optimizing primer concentration for both the indi-
vidual primer pairs as well as the overall pools, the same
13 clinical FFPE samples previously used on the Fluidigm
platform were subjected to the custom bisulfite multiplex
assay. Barcoding of the final libraries demonstrated that alleight pools were giving high-quality libraries (Figure 3A,B)
and even substantially degraded FFPE DNA which com-
pletely failed in Fluidigm Access Array performed robustly
(lanes 8 to 10 in Figure 3B, as compared to Fluidigm
libraries in Figure 2C). These clinical samples were also
sequenced using the Illumina MiSeq (Illumina, San Diego,
CA) to determine the proportionality of amplicon repre-
sentation and overall methylation state; libraries for each
clinical sample were prepared three times on different days
to assess reproducibility, and methylated control samples
were also included.
Of the 57 amplicons assayed, only one amplicon was
observed to consistently fail across all samples, and the
remaining 56 amplicons were all present in the assay. Of
the 56 amplicons remaining, the total reads for most
amplicons were typically observed to be within an order
of magnitude of each other, with the difference in total
read numbers between the amplicons with the lowest
and highest counts typically showing no more than two or-
ders of magnitude difference (Additional file 3: Figure S3).
The variability and reproducibility in the proportions of
each pool as a total amount of each library were also deter-
mined, and the amount of each pool as a percentage of
each library was calculated. Across 13 samples amplified in
triplicate, pool proportionality was maintained within simi-
lar values across all samples and libraries (Figure 4A), with
standard deviations of pool proportions less than 3%
(Figure 4B). Although pool 7 was observed to dominate all
sequencing libraries, subsequent experiments using a re-
duced concentration of primers for pool 7 reduced the
amount present to levels proportional with the other pools
(data not shown).
To assess reproducibility of amplicon coverage, the rep-
resentation of each amplicon across the 54 libraries was
determined, after normalizing the total number of reads
for an amplicon based on its pool of origin. This analysis
showed that while there was a broad distribution of reads/
amplicons (Figure 4C), each amplicon was maintained at
moderately consistent values across all 54 samples, with
most amplicons exhibiting less than 8% variability in total
read numbers between samples and replicates (Figure 4C).
Reproducibility of methylation levels across a region of
interest
To assess assay reproducibility in determining the methy-
lation state, 293 CpGs were examined in triplicate across a
separate set of 13 different tumour samples. Overall assay
performance based on methylated controls and clinical
FFPE tumour samples indicated consistent assay per-
formance. A representative region along with methyl-
ated controls is shown in Figure 5 for 13 CpGs; a larger
bias plot showing representative data across 68 CpGs is
also shown in Additional file 4: Figure S4. The lowest SD
observed across 293 CpGs was 0.0043%, with a mean SD
A B
Figure 3 Representative libraries prepared using the custom bisulfite PCR multiplex assay. After optimizing primer concentration for the
individual primer pairs as well as the overall pools, barcoding of the final libraries demonstrated that the assay performed well on both high-quality
white blood cell DNA (A) and degraded clinical FFPE samples (B). In comparison, even substantially degraded FFPE DNA which completely failed in
Fluidigm Access Array (lanes 8 to 10 in Figure 2C) performed well with this multiplex assay (panel B lanes 1 to 3).
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however, this high value was due to one erratic amplicon
which gave consistently high SDs across its length, and
after this amplicon was removed, the maximal SD observed
across 281 CpGs dropped to 8.04% (Additional file 5:
Table S1). Moreover, although standard deviation values
are present in Figure 5, they were observed to be so
small that the standard deviation spread is not readily
visible, and for this reason, the values have been included
in a separate table (Additional file 6: Table S2).
Conclusions
There is a requisite need for scalable and cost-effective
resequencing strategies, particularly as relates to methyla-
tion analysis of clinical FFPE samples by bisulfite PCR. For
example, the recent explosion of data from the TCGA
with respect to cancer methylated biomarkers first re-
quires validation by independent labs before they can be
confidently translated to a clinical setting. To address
this need, we have embarked on a comprehensive set of
optimization experiments focused on a scalable resequen-
cing protocol for bisulfite PCR applications. Our analysis
involved a highly detailed deconstruction of the key pa-
rameters required for effective pre-amplification of bi-
sulfite libraries on the Fluidigm Access Array system
and concluded with a multiplex PCR protocol which is ef-
fective for use with both gDNA and bisulfite DNA samples.
Two key features of this assay are the ability to generate
high-quality resequencing libraries using degraded FFPE
samples and the ability to use subnanogram amounts of
clinical DNA per amplicon once sufficient multiplexability
is reached.
An alternate platform for high-throughput resequencing
is the Fluidigm Access Array system, which employs nano-
fluidics for high-throughput PCR amplification and enables
analysis of multiple amplicons across 96 samples simultan-
eously. While this platform has been used for somatic mu-
tation screening of clinical FFPE DNA, at present, there is
only one report in the literature on its use for bisulfite PCR
applications [12], and to date, no assessment has been per-
formed on its utility when using bisulfite-converted clinicalFFPE DNA samples. To evaluate the effectiveness of this
platform for high-throughput methylation analysis, we
therefore embarked on a comprehensive series of bisulfite
PCR optimization experiments. In conducting these
optimization experiments, we concluded that the small
nanoliter size of the reaction chamber in an Access Array
chip made the assay highly sensitive to the number of cop-
ies present for amplification; following the recommended
Fluidigm protocol would deliver approximately 100 copies
of template per well, in the absence of pre-amplification.
However, in instances where the sample DNA quantita-
tion is less than completely accurate, and/or when the
sample may be partially degraded due to FFPE fixation
and extraction, this recommendation would almost cer-
tainly result in fewer than 100 copies of DNA being ana-
lyzed, which risks introducing substantial bias in the
methylation analysis. For this reason, we attempted to
employ a pre-amplification strategy when working with
our clinical FFPE samples on the Access Array system. In
doing so, one recurring theme in optimizing the Access
Array for use in bisulfite PCR was the sensitivity of the
platform to minor differences in pre-amplification param-
eters. Our extensive optimization experiments indicated
that a template of moderately high quality would require
approximately 20 cycles of multiplex pre-amplification,
another 35 cycles of singleplex amplification on the Flui-
digm Access Array, and finally an additional 15 cycles of
barcoding PCR, for a total of 70 cycles of amplification.
However, it is generally accepted that when generating
NGS libraries, total amplification cycles should be kept to
an absolute minimum, and this is considered even more
critical when working with bisulfite PCR as a high number
of PCR cycles can skew methylation percentages [14]. Al-
though it was possible to slightly reduce the total number
of cycles, subtle differences in amplification parameters
(that is, 50 vs 200 nM primer pool, 15 vs 20 cycles of pre-
amp PCR) were observed to completely alter the success
and failure of bisulfite libraries on the Fluidigm system.
This suggests a sensitivity to template quality and in-
put which can be difficult to guarantee when working
with degraded FFPE samples, even after pre-amplification
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Pool1             1.54
Pool2             2.45
Pool3             1.08
Pool4             0.73
Pool5             1.57
Pool6             0.63
Pool7             2.95
Pool8             1.16
Average Pool Standard Deviation
D
B
Figure 4 Sequencing results. Sequencing results for libraries prepared in triplicate for 13 FFPE tumour samples, as well as a series of 5 methylated
controls (0%, 25%, 50%, 75%, and 100%) using the custom bisulfite PCR multiplex assay. (A) The proportions of each pool across 54 libraries, determined
as a total amount of each library. Y-axis: Percentage of total library = Total number of reads for a pool ÷ Total number of reads for the library. Although pool
7 was observed to dominate all libraries, the proportion of each pool across 54 samples was maintained at consistent levels. Whiskers: 10th to
90th percentiles; black circles: 5th and 95th percentiles. (B) The average standard deviation in 8-plex pool proportions observed across all
libraries. Average pool standard deviation = (The sum of all standard deviations for a single pool ÷ The total number of entries, that is, the mean
value). Across 13 FFPE samples amplified in triplicate, pool proportionality was maintained within similar values across all samples and libraries.
(C) The proportion of each amplicon in each of the libraries, calculated as a percentage of its original 8-plex pool. Percentage pool proportion = Total
number of reads for an amplicon ÷ Total number of reads for its pool. Whiskers: 10th to 90th percentiles; black circles: 5th and 95th percentiles.
(D) Histogram showing the distribution of the average standard deviations for all 57 amplicons in the assay. Across 13 FFPE samples amplified in triplicate,
the proportion of each of the 56 amplicons was maintained at consistent levels. Average standard deviation= The sum of all standard deviation values for
a single amplicon (as a percentage of its original 8-plex pool as outlined in C) ÷ The total number of entries.
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Figure 5 Representative methylation results. Representative data of 4 out of the 13 clinical FFPE samples assayed are shown. FFPE breast
tumour samples were assayed in triplicate, along with a set of methylation controls (0%, 25%, 50%, 75%, and 100% methylation controls).
Whereas the methylation values for the control samples were observed to be maintained at consistent levels across the region of interest,
the breast cancer samples were observed to give unique patterns of methylation.
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one option could be to increase the total DNA input
amount (that is, from 50 to 150 ng), we considered this an
unideal option, as clinical DNA is limiting and only the
minimum amount necessary should be used. As such,
while the recommended pre-amplification parameters for
the Access Array may be effective for genomic DNA, they
were insufficient when working with bisulfite-converted
clinical FFPE samples.
In response to these challenges, we developed a
multiplex PCR assay for bisulfite libraries which uses
the same recommended template input amount as the
Fluidigm Access Array system (50 ng), but which offers
higher sensitivity, cheaper costs, and faster turnaround
times. While the Fluidigm system can potentially offer
greater sample throughput based on multiplexing the
primer input nanowells, in our experience, this has led
to substantial dimer products in the final library. More-
over, successful library construction ultimately required
over 70 rounds of PCR amplification, which risked
introducing artefact and bias into methylation analysis
[14]. In contrast, our optimized protocol requires only
30 rounds of amplification from start to finish and is
suitable for both genomic and bisulfite-converted DNA
applications. Moreover, the lowest SD observed across
the entire assay was 0.0043%, with a mean SD across all
293 CpGs of only 1.5%. Although we did not perform a
comparison of methylation values between tumour
samples and normal controls in this manuscript, webelieve the high reproducibility of our assay will sup-
port robust statistical comparisons between healthy and
pathogenic samples and/or fixed and unfixed samples.
To date, this assay has been performed over 200 times
on FFPE DNA samples with excellent success, and we are
confident that improvements to the assay will continue to
increase both the throughput and sensitivity, as well as
reduce the total amplification cycles needed.Methods
Fusion primer sequences
Fusion primer sequences used were as follows: M13F,
GTAAAACGACGGCCAG; M13R, CAGGAAACAGC
TATGAC; Ion P, CCTCTCTATGGGCAGTCGGTGAT;
Ion A1, CTGCTGTACGGCCAAGGCG; CS1, ACACT
GACGACATGGTTCTACA; and CS2, TACGGTAGCA
GAGACTTGGTCT.
Bisulfite DNA conversions were performed using either
manual protocols [15] or commercial kits (MethylEasy
Xceed P/N ME002, Human Genetic Signatures, North
Ryde, NSW, Australia), as per the manufacturer’s proto-
cols. For each conversion, DNA was first quantified with
the Qubit dsDNA BR Assay Kit (Life Technologies, Grand
Island, NY, USA), and based on the available sample ma-
terial, between 100 ng and 1 μg of material was bisulfite
converted at a time. Conversion took place at 80°C for 45
min, followed by resuspension in low TE (10 mM Tris-Cl,
pH 8.0, 0.1 mM EDTA).
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A PCR Master Mix recipe for bisulfite-converted DNA re-
agents was made using a 100-μl standard reaction using
the following recipe. Promega Hot Start GoTaq with Flexi
buffer (M5005) was used. The final PCR reaction had the
following components at the indicated concentrations:
5× green (1×), CES 5×, (0.5×, N.B. refer to [16] for CES
recipe), MgCl2 (4.5 mM), dNTPs (200 μM each),
primers (forward and reverse at 100 mM), Hot Start
Taq (0.025 U/μl), DNA (2 ng/μl). Amplification took
place on either an Eppendorf ProS 96 well or an Eppendorf
Pro 384 well thermocycler (Eppendorf, Hamburg, Germany).
Cycling conditions were as follows: 94°C, 5 min; 12 cycles
(95°C, 20 s; 60°C, 1 min); 12 cycles (94°C, 20 s; 65°C, 1 min
30 s); and 65°C, 3 min, 10°C hold. PCR products were evalu-
ated using standard agarose gel electrophoresis techniques
with SB buffer. ExoSAP-IT (P/N 78201 1 ML, Affymetrix,
Santa Clara, CA, USA) was used to remove residual pri-
mer leftovers in the PCR, and the reaction was carried
out according to the manufacturer’s protocol.
Barcoding PCR conditions
In a 100-μl reaction, the following were the final concen-
trations: 1× GoTaq Green Flexi buffer; 0.25× CES; 4.5 mM
MgCl2; 200 μM dNTPs; 0.05 U/μl Hot Start Taq; 25 μl of
pooled template after Agencourt XP bead cleanup; and
20 μl MiSeq (Fluidigm PN FLD-100-3771) or Ion Torrent
(200 nM). Amplification took place on either an Eppen-
dorf ProS 96 well or Eppendorf Pro 384 well thermocycler.
Cycling conditions were as follows: 94°C, 5 min; 9 cycles
(97°C, 15 s; 60°C, 30 s; 72°C, 2 min); 72°C, 2 min; and 6°C,
5 min. The Access Array system was run according to the
manufacturer’s recommended protocols.
Copy number calculations
1 bp dsDNA = 615 g/mol. 1 human genome = 3e9 dsDNA
bases. ((615 g/mol/dsDNA base) × (3e9 dsDNA bases))/
6.022e23 = 3.075 pg/human genome.Fluidigm copy number/well calculations
50 ng × 333 DNA copies/ng of DNA= 16,650 DNA copies;
16,650 copies ÷ 5,000 nl = 3.33 copies/nl; (30 nl Access
Array well) × (3.33 copies/nl) = 100 copies/nanowell.
Fluidigm Access Array volume calculations
48 nanowells × 30 nl = 1,440 nl; 1,440 nl/5,000 nl total vol-
ume = 28.8% volume which participates in amplification.
Cells and DNA extractions
MCF7 cells were used for control cell line DNA. DMEM
supplemented with 10% FBS, 10 μg/ml insulin, 1 mM
sodium pyruvate, and 1× antibiotic/antimycotic was
used. DNA extractions from cell line DNA utilized theDNeasy Blood and Tissue Kit from Qiagen (Venlo, The
Netherlands), according to the manufacturer’s protocol.
Clinical samples were extracted from FFPE blocks using
the PAXgene Tissue DNA Kit (PN 767134, Qiagen) ac-
cording to the manufacturer’s instructions. Five 8-μm
sections were processed at a time for each tissue block,
although the amount of tissue material for each speci-
men varied.Methylated controls
One hundred percent methylated DNA was commercially
sourced from NEB (CpG Methylated Jurkat Genomic
DNA, Cat# N4002S). Zero percent methylated DNA was
created by performing whole-genome amplification of
commercially bought human genomic DNA (Roche
Human Genomic DNA Cat# 11691112001), using the
Qiagen REPLI-g whole-genome amplification kit, ac-
cording to the manufacturer’s instruction. Graduated
methylated controls (that is, 25%, 50%, 75%) were made
by determining the amount of amplifiable DNA in the
100% and 0% methylated DNA samples using qPCR and
pooling 0% and 100% methylated DNA in the proportions
needed to produce the final methylated control.
Sequencing was performed on either a MiSeq or Ion
Torrent sequencer. MiSeq runs used the MiSeq Reagent
Kit v2 (300 cycles; PN MS-102-2002). PGM runs used ei-
ther the OT2 200 bp and 200 bp Ion PGM Sequencing
Kit (Life Technologies) with a 314 chip or the OT2 400 bp
kit and the 400 bp Ion PGM Sequencing Kit with a 314v2
chip. MiSeq sequencing utilized custom sequencing adap-
tors, as described in the Fluidigm Access Array manual.Bioinformatics
Adaptor trimming employed Trim galore (options: –length
100). Mapping used the Bismark methylation mapping
program [17] running Bowtie2 [18] (options: –bowtie2 -N
1 -L 15 –bam -p 2 –score L,-0.6,-0.6 –non_directional; bis-
mark_methylation_extractor -s -merge_non_CpG –com-
prehensive –cytosine_report). To reduce computational
overhead, mapping took place against only those genomic
regions which were being investigated, plus an additional
100 bp to 1 kb of flanking sequence. Graphing and analysis
employed SigmaPlot 12.5 and Excel 2010.Additional files
Additional file 1: Figure S1. To assess the performance of different
fusion sequences in targeted resequencing, seven different pairs of bisulfite
PCR primers were evaluated with and without additional sequences added
to their 5' end. (−) = No template control; Std = primers with no fusion
sequence; M13 = primers with M13 sequences; Ion = primers with Ion
Torrent P and A1 sequences; Fld = Fluidigm’s CS sequences. Although all
primer sets performed well under stringent conditions, only Fluidigm’s CS
sequences gave no observable dimer product in the negative control.
Korbie et al. Clinical Epigenetics  (2015) 7:28 Page 11 of 11Additional file 2: Figure S2. Thirty gDNA primer pairs were divided
equally into six pools and amplified concurrently at four different primer
concentrations. Each pool was then sequenced on either an Ion Torrent
(A) or MiSeq (B) to assess individual amplicon proportion, as well as
whether particular sequencing platforms alter amplicon proportionality.
The Y-axis represents the percentage proportion for each amplicon, as a
total of its particular multiplex pool. Whiskers: 10th to 90th percentiles;
black circles: outliers.
Additional file 3: Figure S3. The distribution of read counts for 56
bisulfite DNA amplicons across 54 libraries. Although the spread in read
numbers between the lowest and highest amplicons for each library is less
than two orders of magnitude (that is, 200 to 20,000), the majority of
amplicons have read counts which cluster within one order of magnitude
of each other. Whiskers: 10th to 90th percentiles; black circles: 5th and 95th
percentiles.
Additional file 4: Figure S4. Representative methylation bias plot for 68
CpGs across 8 amplicons in the library. Although particular CpG positions
are observed to deviate from the median value (for example, CpG 62 and
64), overall, the assay is able to distinguish between different methylation
percentages across every CpG.
Additional file 5: Table S1. Spread of standard deviation methylation
values across Watson strand amplicons, based on three technical replicates.
The maximal standard deviation observed in this dataset was due to a single
amplicon at low coverage; removing this amplicon reduced the maximum
standard deviation observed for a single CpG from 23.8% to 8.04%.
Additional file 6: Table S2. Standard deviation values for tumour
samples 1 to 13 across three technical replicates for one representative
amplicon (N.B. Only samples 1 to 4 are shown in Figure 5). The standard
deviation represents the value by which the technical replicates for each
sample deviate from the mean percent methylation value.
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